Literature DB >> 16262966

Marginal cost of operating a positron emission tomography center in a regulatory environment.

Anderson Chuck1, Philip Jacobs, J Wayne Logus, Donald St Hilaire, Chester Chmielowiec, Alexander J B McEwan.   

Abstract

OBJECTIVES: Cost studies of positron emission tomography (PET) imaging are important for resource and operational planning; the most relevant cost analysis in this regard is the marginal cost. Operating within a regulatory environment can add considerably to the costs of providing PET services. Previously published research has not examined the marginal cost structure of PET nor have they described the implications of regulatory compliance to operational costs. The purpose of this study was to conduct a comprehensive cost estimation of PET imaging with 18F-fluorodeoxyglucose (18F-FDG) to better identify the fixed and variable cost components, the marginal cost structure, and the added costs of satisfying regulatory requirements.
METHODS: Financial data on capital and operating expenses were collected for the PET center at the Cross Cancer Institute in Edmonton, Alberta, Canada.
RESULTS: The total per-service cost for clinical operations ranged between $7,869 (400 annual scans) and $1,231 (3,200 annual scans). The marginal cost for the center remained steady as volume increased up to the throughput capacity.
CONCLUSIONS: Results indicate that economies from increased volumes did not arise. Regulatory requirements added significant costs to operating an 18F-FDG-PET center.

Entities:  

Mesh:

Year:  2005        PMID: 16262966     DOI: 10.1017/S0266462305050610

Source DB:  PubMed          Journal:  Int J Technol Assess Health Care        ISSN: 0266-4623            Impact factor:   2.188


  8 in total

1.  On the significance of defective block detectors in clinical (18)F-FDG PET/CT imaging.

Authors:  Esmat Elhami; Maryam Samiee; Sandor Demeter; William D Leslie; Andrew L Goertzen
Journal:  Mol Imaging Biol       Date:  2011-04       Impact factor: 3.488

2.  Is a methodology available that accurately measures the cost of an FDG-PET study?

Authors:  Bruno Krug; Anne Sophie Pirson; Ralph Crott; Thierry Vander Borght
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-12-08       Impact factor: 9.236

3.  Activity-based costing evaluation of [18F]-fludeoxyglucose production.

Authors:  Bruno Krug; Annie Van Zanten; Anne-Sophie Pirson; Ralph Crott; Thierry Vander Borght
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-09-21       Impact factor: 9.236

Review 4.  Is there still a role for SPECT-CT in oncology in the PET-CT era?

Authors:  Rodney J Hicks; Michael S Hofman
Journal:  Nat Rev Clin Oncol       Date:  2012-11-13       Impact factor: 66.675

5.  Unexpected Benefit of the Positron Emission Tomography/Computed Tomography Using 18F-Fluorodeoxyglucose: Report of a Case.

Authors:  Cemil Caliskan; Can Karaca; Mustafa Ozsoy; Erhan Akgun; Mustafa A Korkut
Journal:  Indian J Surg       Date:  2016-04-06       Impact factor: 0.656

Review 6.  A systematic review of PET and PET/CT in oncology: a way to personalize cancer treatment in a cost-effective manner?

Authors:  Astrid Langer
Journal:  BMC Health Serv Res       Date:  2010-10-08       Impact factor: 2.655

7.  Three-year follow-up of de-escalated axillary treatment after neoadjuvant systemic therapy in clinically node-positive breast cancer: the MARI-protocol.

Authors:  Ariane A van Loevezijn; Marieke E M van der Noordaa; Marcel P M Stokkel; Erik D van Werkhoven; Emma J Groen; Claudette E Loo; Paula H M Elkhuizen; Gabe S Sonke; Nicola S Russell; Frederieke H van Duijnhoven; Marie-Jeanne T F D Vrancken Peeters
Journal:  Breast Cancer Res Treat       Date:  2022-03-03       Impact factor: 4.872

Review 8.  Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer's disease and mild cognitive impairment.

Authors:  Avinash Chandra; Polytimi-Eleni Valkimadi; Gennaro Pagano; Oliver Cousins; George Dervenoulas; Marios Politis
Journal:  Hum Brain Mapp       Date:  2019-09-14       Impact factor: 5.038

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.